TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CD20+ B-cell lymphoma or B-CLL~* Refractory/relapsed CLL, FL, and DLBCL~* At least 1 measurable lesion (greater than \[\>\] 1.5 centimeters \[cm\] in its largest dimension) with the exception of CLL~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy \>6 months~Exclusion Criteria:~* Prior use of any investigational antibody therapy within 6 months of study start~* Prior use of any anti-cancer vaccine~* Prior administration of rituximab within 3 months of study start~* Prior administration of radioimmunotherapy 3 months prior to study entry~* Central nervous system lymphoma~* History of other malignancy~* Evidence of significant, uncontrolled concomitant disease~* Abnormal laboratory values~* Patients with progressive multifocalleukoencephalopathy (PML)~* Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
- DLBCL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
- FL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Green Tea and Tai Chi for Bone Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women at least 2 years after menopause (to ensure established postmenopausal status).~* Sedentary at baseline.~* Normal laboratory evaluation, thyroid function, hepatic function, renal function.~* Osteopenia.~Exclusion Criteria:~* History of scoliosis, severe osteoarthritis, etc., or other spinal disease that may result in anatomy unsuitable for accurate bone densitometry.~* History of cancer with some exceptions.~* History of metabolic bone disease.~* Having used anabolic steroids, calcitonin, calcitriol, alfacalcidol, etc.~* Fluoride treatment at a dose greater than 1 mg/day any time.~* History of glucocorticoid treatment.~* Any previous treatment with bisphosphonates.~* Uncontrolled intercurrent illness such as symptomatic congestive heart failure, myocardial infarction or stroke, hypertension, or terminal illness.~* Physical conditions that preclude participation of exercise intervention.~* Cognitive impairment.~* Depression.~* History of malabsorption syndrome and uncontrolled diabetes mellitus.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo pill (Type: PLACEBO_COMPARATOR): 24 weeks of placebo.
- Green Tea Polyphenols (GTP) (Type: ACTIVE_COMPARATOR): 24 weeks of green tea polyphenols
- Placebo+Tai Chi (TC) (Type: ACTIVE_COMPARATOR): 24 weeks of placebo plus Tai Chi exercise.
- GTP+TC (Type: ACTIVE_COMPARATOR): 24 weeks of green tea polyphenols plus Tai Chi exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected adults aged more than or equal to 18 years~2. Received ritonavir boosted PI-based HAART for \>3 months prior screening visit~3. History of HIV RNA \< 50 copies/ml within 12 months prior to screening visit~4. HIV-RNA \< 50 copies/ml at screening visit~5. Signed written informed consent~Exclusion Criteria:~1. Active AIDS-defining disease or active opportunistic infection~2. History of virological failure (plasma HIV-RNA ≥1,000 copies/ml) while using any ritonavir boosted PI-based HAART~3. Pregnancy or lactation at screening visit~4. Relevant history or current conditions or illnesses that might interfere with drug absorption, distribution, metabolism or excretion e.g. chronic diarrhea, malabsorption~5. Use of concomitant medication that may interfere with the pharmacokinetics of the study drugs e.g. rifampicin, proton pump inhibitor~6. History of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study~7. ALT ≥200 IU/L at screening visit~8. Creatinine clearance \< 60 c.c. per min by Cockroft-Gault formula at screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ATV/r 200 mg/100 mg OD
- 2 (Type: EXPERIMENTAL): ATV/r 300 mg/100 mg OD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* 1-3 oral treatments~* Insulin naive~* BMI (Body Mass Index) less than or equal to 45~Exclusion Criteria:~* Pregnancy~* Retinopathy~* Cardiac disease~* Uncontrolled hypertension~* Recurrent hypoglycaemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FPG 70-90 mg/dL (Type: EXPERIMENTAL): Aggressive FPG (fasting plasma glucose) titration target range group
- FPG 80-110 mg/dL (Type: EXPERIMENTAL): Conventional FPG (fasting plasma glucose) titration target range group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Have a diagnosis of cancer and be chemotherapy naive.~* Must be scheduled to receive a chemotherapy treatment containing doxorubicin hydrochloride, epirubicin hydrochloride, cisplatin, carboplatin, or oxaliplatin (any dose or schedule) without concurrent radiotherapy or interferon treatment~* Chemotherapy may be for adjuvant, neoadjuvant, curative or palliative intent.~* Dose-dense regimens (e.g. chemotherapy with doxorubicin or epirubicin given every two weeks)are allowed.~* For the purposes of this study, Day 1 of chemotherapy will be defined as the day of administration of cisplatin, carboplatin, oxaliplatin, doxorubicin or epirubicin.~* Regimens with multiple-day doses of doxorubicin, epirubicin, cisplatin, carboplatin, oxaliplatin, dacarbazine, hexamethylmelamine, nitrosoureas, or streptozocin are not allowed. Chemotherapy agents, other than those listed above, may be given orally, intravenously, or by continuous infusion on one or multiple days.~* Able to understand English~Exclusion criteria:~* No symptomatic brain metastases~* No concurrent or impending bowel obstruction~* Regimens containing liposomal doxorubicin or cisplatin are not allowed.~* No concurrent pimozide, terfenadine, astemizole, or cisapride~* No concurrent doxorubicin hydrochloride liposome or cisplatin~* No concurrent multiple-day doses of dacarbazine, altretamine, nitrosoureas, streptozocin, cisplatin, carboplatin, or oxaliplatin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
- Arm II (Type: EXPERIMENTAL): Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
- Arm III (Type: ACTIVE_COMPARATOR): Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
- Arm IV (Type: EXPERIMENTAL): Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Aged 2 months (42 to 98 days) at time of enrollment.~2. Available for entire study period and whose parent/legal guardian can be reached by telephone.~3. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.~4. Parent/legal guardian must be able to complete all relevant study procedures during study participation.~Exclusion criteria:~1. Previous vaccination with licensed or investigational pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, or polio vaccines.~2. A previous anaphylactic reaction to any vaccine or vaccine-related component.~3. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, hepatitis B, measles, mumps, rubella, or pneumococcal vaccines.~4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~5. Known or suspected immune deficiency or suppression.~6. History of culture-proven invasive disease caused by S pneumoniae.~7. Major known congenital malformation or serious chronic disorders.~8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb palsy.~9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis®).~10. Participation in another investigational or interventional trial. Participation in purely observational studies is acceptable.~11. Infant who is a direct descendant (child or grandchild) of a member of the study site personnel.

- Gender: ALL
- Minimum Age: 41 Days
- Maximum Age: 99 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Troglitazone in Treating Patients With Liposarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven liposarcoma that is incurable by standard surgery Measurable or evaluable disease required No active CNS involvement or leptomeningeal disease~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT less than 5 times upper normal limit Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No poorly controlled atrial arrhythmias, angina pectoris, or myocardial infarction within past 6 months No symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within past 3 months Other: Not pregnant or nursing Fertile patients must use effective contraception No known active retroviral disease~PRIOR CONCURRENT THERAPY: Recovered from toxic effects of all prior therapy No concurrent cytotoxic therapy Biologic therapy: Not specified Chemotherapy: Prior chemotherapy allowed Endocrine therapy: No concurrent hormonal therapy Radiotherapy: Prior radiation therapy for metastatic disease allowed No radiotherapy to sole site of measurable disease within past 6 months Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Troglitazone (Type: EXPERIMENTAL): Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Darbepoetin Administration to Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 500-1250 grams birth weight~* less than or equal to 32 weeks gestation~* less than 2 days of age~Exclusion Criteria:~* severe hemorrhagic disease~* severe hemolytic disease~* DIC~* seizures~* hypertension~* thromboses~* receiving erythropoietin

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 49 Hours
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa injection (Type: EXPERIMENTAL): Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
- erythropoietin alfa injection (Type: ACTIVE_COMPARATOR): Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
- placebo/control (Type: PLACEBO_COMPARATOR): Sham injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association)~* Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review \& Assessment Service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed~* Participants determined to be eligible as subjects at the discretion of the investigator~* Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information~Exclusion Criteria:~* Participants who had administered pravastatin prior to study participation~* Participants with hypersensitivity to the investigational product or its history~* Participants with an active liver disease or persistent elevation of transaminase with an unknown cause~* Pregnant woman or women with childbearing potential, breastfeeding mothers~* Children~* Participants with severe hepatic or renal insufficiency~* Participants with myopathy~* Participants with cholestasis~* Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation~* Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dyslipidemic participants with Type 2 diabetes (Type: None): Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Thoracic and Neck and Upper Extremity Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of at least 18 years of age~* Subjects with a history of chronic, function-limiting thoracic or cervical pain with or without upper extremity pain of at least 6 months in duration~* Subjects who are able to give voluntary, written informed consent to participate in this investigation~* Subjects who, in the opinion of the PI, are able to understand this investigation, co-operate with the investigational procedures, and are willing to return to the center for all the required post-operative follow-ups~* Subjects have not had recent surgical procedures within the last 3 months.~Exclusion Criteria:~* Compressive radiculopathy~* Narcotic use of no greater than hydrocodone 100 mg/day, methadone of 60 mg, or morphine 180 mg, or dose equivalent~* Uncontrolled major depression or uncontrolled psychiatric disorders~* Uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency, chronic liver dysfunction, progressive neurological deficit, urinary sphincter dysfunction, infection, increased intracranial pressure, pseudotumor cerebri, intracranial tumors, unstable angina, and severe chronic obstructive pulmonary disease~* Chronic severe conditions that could interfere with the interpretations of the outcome assessments for pain and bodily function~* Women who are pregnant or lactating~* Subjects who have participated in a clinical study with an investigational product within 30 days of enrollment~* Patients with multiple complaints involving concomitant shoulder osteoarthritis, due to the overlap of pain complaints~* Inability to achieve appropriate positioning and inability to understand informed consent and protocol~* History of adverse reaction to local anesthetic or anti-inflammatory drugs and history of gastrointestinal bleeding or ulcers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xylocaine (Type: ACTIVE_COMPARATOR): 0.5% Xylocaine
- Xylocaine and Celestone (Type: ACTIVE_COMPARATOR): 0.5% Xylocaine with 6 mg of non-particulate Celestone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologically confirmed locally advanced or stage IV NSCLC~* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2~* Tumor tissue sections must be available for biomarker evaluation~Exclusion Criteria:~* Untreated or active/progressing Central Nervous system (CNS) metastases~* Active, known or suspected autoimmune disease~* Known history of testing positive for HIV or AIDS~* Active or chronic infection of hepatitis B virus or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A Nivolumab (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group A Nivolumab + SOC maintenance therapy (Type: EXPERIMENTAL): Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days
- Group A SOC maintenance therapy (Type: ACTIVE_COMPARATOR): Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days
- Group B Nivolumab (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group B Best supportive care (Type: OTHER): Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
- Group C Investigator's choice chemotherapy (Type: ACTIVE_COMPARATOR): Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days
- Group C Nivolumb (Type: EXPERIMENTAL): Opdivo specified dose on specified days
- Group D Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib specified dose on specified days
- Group D Nivolumab + Erlotinib (Type: EXPERIMENTAL): Opdivo/Erlotnib specified dose on specified days
- Group E Nivolumab + Crizotinib (Type: EXPERIMENTAL): Opdivo/Crizotinib specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete